If You Skye Gailing Family people liking life feelings If You Skye Gailing

So You Think You Need a Migraine Diagnosis?

Reading now: 221

The foundational building block of living with migraine starts with a diagnosis (our insurance companies tell us they need it?).

In this episode, Kat and Skye share their own migraine diagnosis stories, discuss the differences between neurologists and headache specialists, when it might be time to seek out professional help, and share a few starter Qs for your first (or tenth) appointment.

You can also listen on our Spotify for Podcasters page and on Apple Podcasts. Additional Reading: 13 Questions You Should Ask Your Doctor If You Have Migraine 7 Conditions People With Migraine Were Misdiagnosed With Episode Transcript: Skye Gailing  Welcome to Health and (un)Wellness. Kat Harrison  A podcast brought to you by The Mighty, where we put the human back in health.

Read more on themighty.com
The website mental.guide is an aggregator of articles from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the article if you find it unreliable.

Related articles

LSD, MDMA, Magic Mushrooms Clinical Trial Guidelines Released by FDA
July 7, 2023The Food and Drug Administration (FDA) has issued its first-ever draft guidance for clinical trials of psychedelic drugs to treat conditions including depression, mood disorders, anxiety, post-traumatic stress disorder, and substance use disorder.The guidance aims to address the unique challenges inherent in testing “classic psychedelics,” such as psilocybin (magic mushrooms) and lysergic acid diethylamide (LSD), and “entactogens” or “empathogens,” such as methylenedioxymethamphetamine (MDMA) for treating psychiatric conditions that failed to respond to other therapies. The FDA recommends clinical trial considerations regarding subject safety, data collection, manufacturing controls, and drug application requirements.Ultimately, “the goal is to help researchers design studies that will yield interpretable results that will be capable of supporting future drug applications,” said Tiffany Farchione, M.D., director of the Division of Psychiatry in the FDA’s Center for Drug Evaluation and Research, in a statement last month.In February 2022, researchers from Johns Hopkins Medicine reported that psilocybin-assisted therapy for major depressive disorder produced antidepressant effects up to 12 months after treatment.1Ari Tuckman, Psy.D., and Stephanie Sarkis, Ph.D., recently told ADDitude that using very low (micro) doses of psychedelics, such as LSD and psilocybin is gaining renewed attention as a treatment for anxiety and depression.